Leading product leverage RELIZORB’s established use to improve fat hydrolysis in enteral nutrition across pediatric and adult populations represents a ready-to-pitch value proposition for hospitals, pediatric centers, CF clinics, and long-term care facilities seeking to optimize nutritional delivery and outcomes.

Expansion-ready opportunity FDA clearance updates expanding RELiZORB use for younger pediatric patients (ages 2 to 5) suggest ongoing regulatory progress and potential expansion in care settings, creating a targeted sales window for pediatric and neonatal nutrition programs.

Clinical validation pedigree A history of pivotal trials and peer‑reviewed data, plus recognition as a Medical Device Excellence Award Gold Winner, provides talking points for evidence-based sales conversations with hospital procurement and clinical teams seeking validated enzyme-based enteral solutions.

Strategic partnerships Backed by Linden Capital Partners and HealthQuest Capital and a leadership cadence with a growing Medical Affairs function, there is credibility to engage enterprise accounts, academic centers, and contract research organizations exploring enzyme-based therapies and nutrition optimization.

Market fit signals A focus on gastrointestinal disorders and rare diseases, including cystic fibrosis and preterm-related malabsorption, aligns with niche but sizable market segments and reimbursement pathways, suggesting prioritization of CF centers, neonatology units, gastroenterology clinics, and specialized home nutrition programs.